keyword
https://read.qxmd.com/read/20660574/preclinical-and-clinical-evidence-that-deoxy-2-18f-fluoro-d-glucose-positron-emission-tomography-with-computed-tomography-is-a-reliable-tool-for-the-detection-of-early-molecular-responses-to-erlotinib-in-head-and-neck-cancer
#21
JOURNAL ARTICLE
Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, Ben C Allal
PURPOSE: There is a clinical need to identify predictive markers of the responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography with computed tomography ((18)FDG-PET/CT) could be a tool of choice for monitoring the early effects of this class of agent on tumor activity. EXPERIMENTAL DESIGN: Using models of human head and neck carcinoma (CAL33 and CAL166 cell lines), we first tested in vitro and in vivo whether the in vivo changes in (18)FDG-PET/CT uptake were associated with the molecular and cellular effects of the EGFR-TKI erlotinib...
September 1, 2010: Clinical Cancer Research
https://read.qxmd.com/read/19317609/clinical-significance-of-fdg-single-photon-emission-computed-tomography-computed-tomography-in-the-diagnosis-of-head-and-neck-cancers-and-study-of-its-mechanism
#22
JOURNAL ARTICLE
Ling-Fa Li, Shui-Hong Zhou, Kui Zhao, Shen-Qing Wang, Qiu-Liang Wu, Jun Fan, Ke-Jia Cheng, Ling Ling
BACKGROUND: The metabolic changes of malignant cells are earlier than these of morphology. (18)F-fluorodeoxyglucose (FDG) single-photon emission computed tomography (SPECT)-computed tomography (CT) systems provide functional and anatomic images that could significantly improve its diagnostic capability. The molecular mechanisms of increased FDG uptake are still not fully understood. The correlation between FDG uptake and the expression of Glut in various tumor cells is still under debate...
December 2008: Cancer Biotherapy & Radiopharmaceuticals
https://read.qxmd.com/read/18620902/the-prognostic-value-of-hypoxia-markers-in-t2-staged-oral-tongue-cancer
#23
JOURNAL ARTICLE
Jong-Lyel Roh, Kyung-Ja Cho, Gui Young Kwon, Chang Hwan Ryu, Hyo Won Chang, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
Tumor hypoxia is associated with poorer outcome in patients with head and neck carcinomas, but little is known about hypoxia biomarkers in oral tongue cancer. We evaluated whether hypoxia biomarkers and clinicopathologic variables were prognostic predictors in patients with T2-staged squamous cell carcinoma (SCC) of the oral tongue. Tissue microarrays were constructed from formalin-fixed tumor blocks of 43 patients with T2-staged tongue SCCs treated by surgical resection and neck dissection. Tissue samples were stained with monoclonal antibodies to hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, carbonic anhydrase (CA)-9, glucose transporter (GLUT)-1, and erythropoietin receptor (EPOR)...
January 2009: Oral Oncology
https://read.qxmd.com/read/18401196/expression-of-glucose-transporter-1-and-3-in-the-head-and-neck-carcinoma-the-correlation-of-the-expression-with-the-biological-behaviors
#24
JOURNAL ARTICLE
Shuihong Zhou, Shenqing Wang, Qiuliang Wu, Jun Fan, Qinying Wang
OBJECTIVE: The aim of this study was to determine the biological significance of glucose transporter (Glut)-1 and Glut-3 expression in head and neck carcinoma (HNC). METHODS: We detected expression of Glut-1 and -3 in 38 HNCs and analyzed the relationship between increased expression and the biological behavior of HNCs. RESULTS: The gene expression levels of Glut-1 and -3 in HNCs were significantly higher than those in adjacent cancer tissues or in normal tissues...
2008: ORL; Journal for Oto-rhino-laryngology and its related Specialties
https://read.qxmd.com/read/18281542/hypoxia-selective-targeting-by-the-bioreductive-prodrug-aq4n-in-patients-with-solid-tumors-results-of-a-phase-i-study
#25
MULTICENTER STUDY
Mark R Albertella, Paul M Loadman, Philip H Jones, Roger M Phillips, Roy Rampling, Neil Burnet, Chris Alcock, Alan Anthoney, Egils Vjaters, Chris R Dunk, Peter A Harris, Alvin Wong, Alshad S Lalani, Chris J Twelves
PURPOSE: AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence shows that AQ4N penetrates deeply within tumors and undergoes selective activation to form AQ4, a potent topoisomerase II inhibitor, in hypoxic regions of solid tumors. This proof-of-principle, phase I study evaluated the activation, hypoxic selectivity, and safety of AQ4N in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Thirty-two patients with cancer (8 glioblastoma, 9 bladder, 8 head and neck, 6 breast, and 1 cervix) received a single 200 mg/m(2) dose of AQ4N before elective surgery...
February 15, 2008: Clinical Cancer Research
https://read.qxmd.com/read/18281490/a-retroinhibition-approach-reveals-a-tumor-cell-autonomous-response-to-rapamycin-in-head-and-neck-cancer
#26
JOURNAL ARTICLE
Panomwat Amornphimoltham, Vyomesh Patel, Kantima Leelahavanichkul, Robert T Abraham, J Silvio Gutkind
Emerging evidence supporting the activation of the Akt-mammalian target of rapamycin (mTOR) signaling network in head and neck squamous cell carcinoma (HNSCC) progression has provided the rationale for exploring the therapeutic potential of inhibiting this pathway for HNSCC treatment. Indeed, rapamycin, a clinically relevant mTOR inhibitor, promotes the rapid regression of HNSCC-tumor xenografts in mice. However, rapamycin does not affect the growth of HNSCC cells in vitro, thus raising the possibility that, as for other cancer types, rapamycin may not target cancer cells directly but may instead act on a component of the tumor microenvironment, such as tumor-associated vasculature...
February 15, 2008: Cancer Research
https://read.qxmd.com/read/17440684/hypoxia-in-cancer-significance-and-impact-on-clinical-outcome
#27
REVIEW
Peter Vaupel, Arnulf Mayer
Hypoxia, a characteristic feature of locally advanced solid tumors, has emerged as a pivotal factor of the tumor (patho-)physiome since it can promote tumor progression and resistance to therapy. Hypoxia represents a "Janus face" in tumor biology because (a) it is associated with restrained proliferation, differentiation, necrosis or apoptosis, and (b) it can also lead to the development of an aggressive phenotype. Independent of standard prognostic factors, such as tumor stage and nodal status, hypoxia has been suggested as an adverse prognostic factor for patient outcome...
June 2007: Cancer Metastasis Reviews
https://read.qxmd.com/read/17418018/-value-of-18f-fdg-metabolic-imaging-in-diagnosis-and-treatment-of-head-and-neck-tumors-and-its-mechanism-study
#28
JOURNAL ARTICLE
Shui-Hong Zhou, Qiu-Liang Wu, Shen-Qing Wang, Jun Fan, Ling-Fa Li
OBJECTIVE: To study the value of (18)F-FDG dual-head tomography with coincidence (DHTC) and single photon emission computerized tomography (SPECT) coincidence imaging in diagnosis and treatment of head and neck tumors and mechanism thereof and analyze the value of glucose transporter proteins in the mechanism of increased uptake glucose of head and neck malignant tumor. METHODS: Twenty-five patients with head and neck tumors were examined by CT or MRI and underwent (18)F-FDG DHTC and coincidence imaging...
January 9, 2007: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/16730088/the-prognostic-value-of-endogenous-hypoxia-related-markers-for-head-and-neck-squamous-cell-carcinomas-treated-with-arcon
#29
JOURNAL ARTICLE
Ruth A Jonathan, Karien I E M Wijffels, Wenny Peeters, Peter C M de Wilde, Henri A M Marres, Matthias A W Merkx, Egbert Oosterwijk, Albert J van der Kogel, Johannes H A M Kaanders
BACKGROUND AND PURPOSE: Hypoxic radioresistance is an important cause for treatment failure in a number of tumor types including head and neck cancers. Recent studies suggest that outcome can be improved by oxygenation modifying treatments such as ARCON. A robust endogenous marker of hypoxia might be a valuable aid to select patients for such treatments. The aim of this investigation was to study associations between the putative endogenous hypoxia markers CA-IX, Glut-1 and Glut-3 and clinical tumor and patient characteristics and to evaluate the prognostic value of these markers...
June 2006: Radiotherapy and Oncology
https://read.qxmd.com/read/15468132/diagnostic-value-of-glut-1-immunoreactivity-to-distinguish-benign-from-malignant-cystic-squamous-lesions-of-the-head-and-neck-in-fine-needle-aspiration-biopsy-material
#30
JOURNAL ARTICLE
Michael F Weiner, Roberto N Miranda, Ricardo H Bardales, Perkins Mukunyadzi, Sandra J Baker, Soheila Korourian, Luis E De Las Casas
The distinction of cystic squamous-cell carcinoma (SCC) from benign cystic squamous lesions (BCSLs) of the head and neck can be problematic on fine-needle aspiration biopsy (FNAB) material, particularly when BCSLs display epithelial reactive atypia or when SCC is well differentiated. Glucose transporter 1 (GLUT-1), a facilitative cell surface glucose transport protein, is aberrantly expressed in many cancers including oral and hypopharyngeal SCC. We evaluated the expression of GLUT-1 by immunochemistry on FNAB material to determine its value in distinguishing cystic SCC from BCSL of the head and neck...
November 2004: Diagnostic Cytopathology
https://read.qxmd.com/read/14666730/antiangiogenic-hypoxic-cytotoxin-tx-402-inhibits-hypoxia-inducible-factor-1-signaling-pathway
#31
JOURNAL ARTICLE
Hideko Nagasawa, Naoko Mikamo, Yoshimi Nakajima, Hideki Matsumoto, Yoshihiro Uto, Hitoshi Hori
BACKGROUND: Hypoxia represents an important tumor-specific target for cancer therapy. We have reported that hypoxic cytotoxins, such as TX-1102, tirapazamine (TPZ) and TX-402, selectively induced tumor cells to p53-independent apoptosis under hypoxic conditions and inhibited angiogenesis. MATERIALS AND METHODS: We investigated the effects of the antiangiogenic hypoxic cytotoxins on hypoxia-induced gene expression and their hypoxia-selective cytotoxicity in human squamous cell carcinoma of the head and neck (SAS cells) and p53-deficient human non-small cell lung carcinoma H1299 cells transfected with either wild-type or mutant p53 gene...
November 2003: Anticancer Research
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.